Tesamorelin is a peptide meticulously prepared for scientific inquiry. This product is synthesized with a high purity of 99%. It is developed for use in various laboratory investigations. Tesamorelin is designated solely for research and development purposes.
Tesamorelin's structure is based on the human GHRH (1-44) sequence with a trans-3-hexenoyl group attached to the N-terminal tyrosine, yielding the molecular formula C221H366N72O67S and a molecular weight of approximately 5,135.86 g/mol. This modification confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending its half-life to 26–38 minutes in models and improving bioavailability compared to native GHRH. The peptide's acetate salt form supports subcutaneous administration in studies, with metabolism occurring via proteolysis and excretion primarily renal.
In lab contexts, tesamorelin is provided as a lyophilized powder with purity typically over 98%, confirmed by HPLC and mass spectrometry. It shows good solubility in neutral aqueous buffers, but its stability benefits from the hexenoyl group, which prevents rapid deactivation. Our transparent quality controls ensure each batch is consistent, allowing you to proceed with confidence in your assays.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid sequence of human GHRH with an N-terminal trans-3-hexenoyl modification to enhance stability and potency for stimulating endogenous growth hormone (GH) release in research models. This peptide is engineered to mimic natural GHRH while resisting enzymatic degradation, making it a useful tool for in-vitro explorations of endocrine signaling, metabolic regulation, and fat distribution dynamics. As with all our peptides, tesamorelin is supplied exclusively for research purposes and in-vitro use only—not for human consumption or any clinical applications.
Tesamorelin acts by binding to and activating GHRH receptors on pituitary somatotroph cells, promoting the synthesis and pulsatile release of endogenous GH without altering pulse frequency. This leads to elevated insulin-like growth factor-1 (IGF-1) levels, which regulate body composition through anabolic effects on lean mass and lipolytic actions that reduce visceral fat by inhibiting de novo lipogenesis and enhancing triglyceride breakdown. Unlike direct GH administration, tesamorelin preserves natural feedback mechanisms, potentially minimizing off-target effects in models.
In cellular systems, it may also influence myocardial or metabolic pathways by ameliorating oxidative stress and inflammation, as observed in related GHRH analogs. We enjoy demystifying these processes—tesamorelin provides a refined means to study how modulated GH secretion impacts endocrine balance at the molecular level.
In essence, tesamorelin emerges as a stabilized GHRH analog, enabling researchers to dissect GH regulatory pathways and their impacts on metabolism, repair, and homeostasis through targeted in-vitro stimulation. Its engineered enhancements for potency and durability inspire our collective curiosity in peptide science. Exclusively for research use, tesamorelin exemplifies our dedication to quality tools delivered with approachable expertise and unwavering integrity. Let's team up to illuminate new findings, one well-planned study at a time.
Tesamorelin's ability to augment GH secretion makes it ideal for in-vitro research in lipodystrophy models, metabolic disorders, and tissue repair. In pituitary cell cultures, it has been used to evaluate dose-dependent GH release and gene expression changes, offering insights into somatotroph responsiveness and IGF-1 feedback loops. Metabolic assays often focus on its effects in adipocytes or hepatocytes, where it probes reductions in lipid accumulation and improvements in insulin sensitivity under simulated obese or diabetic conditions.
Beyond metabolism, tesamorelin supports studies in cardiovascular models, demonstrating potential to enhance cell viability and reduce fibrosis in myocardial cultures. Neurological applications include exploring its role in nerve regeneration, with in-vitro work on axonal growth and anti-inflammatory responses in injury-simulated neurons. We recommend it for combination assays with other hormones to uncover synergies, and our educational guidance can help tailor protocols for reproducible, insightful results.
To ensure tesamorelin's integrity in your experiments, store the lyophilized powder at -20°C in a dry, dark environment to protect against degradation. Reconstitute with sterile bacteriostatic water or a neutral buffer to concentrations of 1-2 mg/mL, gently mixing to avoid foaming that could affect stability. Once prepared, aliquot solutions and refrigerate at 2-8°C for short-term use, as freezing reconstituted forms is not recommended.
Our testing verifies resilience, but always confirm pH neutrality and clarity before assays. If you need tips on optimizing for specific media, we're here with practical, evidence-based advice.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the full 44-amino-acid sequence of human GHRH with an N-terminal trans-3-hexenoyl modification to enhance stability and potency for stimulating endogenous growth hormone (GH) release in research models. This peptide is engineered to mimic natural GHRH while resisting enzymatic degradation, making it a useful tool for in-vitro explorations of endocrine signaling, metabolic regulation, and fat distribution dynamics. As with all our peptides, tesamorelin is supplied exclusively for research purposes and in-vitro use only—not for human consumption or any clinical applications.
Tesamorelin acts by binding to and activating GHRH receptors on pituitary somatotroph cells, promoting the synthesis and pulsatile release of endogenous GH without altering pulse frequency. This leads to elevated insulin-like growth factor-1 (IGF-1) levels, which regulate body composition through anabolic effects on lean mass and lipolytic actions that reduce visceral fat by inhibiting de novo lipogenesis and enhancing triglyceride breakdown. Unlike direct GH administration, tesamorelin preserves natural feedback mechanisms, potentially minimizing off-target effects in models.
In cellular systems, it may also influence myocardial or metabolic pathways by ameliorating oxidative stress and inflammation, as observed in related GHRH analogs. We enjoy demystifying these processes—tesamorelin provides a refined means to study how modulated GH secretion impacts endocrine balance at the molecular level.
In essence, tesamorelin emerges as a stabilized GHRH analog, enabling researchers to dissect GH regulatory pathways and their impacts on metabolism, repair, and homeostasis through targeted in-vitro stimulation. Its engineered enhancements for potency and durability inspire our collective curiosity in peptide science. Exclusively for research use, tesamorelin exemplifies our dedication to quality tools delivered with approachable expertise and unwavering integrity. Let's team up to illuminate new findings, one well-planned study at a time.
Tesamorelin's structure is based on the human GHRH (1-44) sequence with a trans-3-hexenoyl group attached to the N-terminal tyrosine, yielding the molecular formula C221H366N72O67S and a molecular weight of approximately 5,135.86 g/mol. This modification confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending its half-life to 26–38 minutes in models and improving bioavailability compared to native GHRH. The peptide's acetate salt form supports subcutaneous administration in studies, with metabolism occurring via proteolysis and excretion primarily renal.
In lab contexts, tesamorelin is provided as a lyophilized powder with purity typically over 98%, confirmed by HPLC and mass spectrometry. It shows good solubility in neutral aqueous buffers, but its stability benefits from the hexenoyl group, which prevents rapid deactivation. Our transparent quality controls ensure each batch is consistent, allowing you to proceed with confidence in your assays.
Tesamorelin's ability to augment GH secretion makes it ideal for in-vitro research in lipodystrophy models, metabolic disorders, and tissue repair. In pituitary cell cultures, it has been used to evaluate dose-dependent GH release and gene expression changes, offering insights into somatotroph responsiveness and IGF-1 feedback loops. Metabolic assays often focus on its effects in adipocytes or hepatocytes, where it probes reductions in lipid accumulation and improvements in insulin sensitivity under simulated obese or diabetic conditions.
Beyond metabolism, tesamorelin supports studies in cardiovascular models, demonstrating potential to enhance cell viability and reduce fibrosis in myocardial cultures. Neurological applications include exploring its role in nerve regeneration, with in-vitro work on axonal growth and anti-inflammatory responses in injury-simulated neurons. We recommend it for combination assays with other hormones to uncover synergies, and our educational guidance can help tailor protocols for reproducible, insightful results.
To ensure tesamorelin's integrity in your experiments, store the lyophilized powder at -20°C in a dry, dark environment to protect against degradation. Reconstitute with sterile bacteriostatic water or a neutral buffer to concentrations of 1-2 mg/mL, gently mixing to avoid foaming that could affect stability. Once prepared, aliquot solutions and refrigerate at 2-8°C for short-term use, as freezing reconstituted forms is not recommended.
Our testing verifies resilience, but always confirm pH neutrality and clarity before assays. If you need tips on optimizing for specific media, we're here with practical, evidence-based advice.
